TEVA Company Profile and Key Details

NYSE : TEVA

Teva Pharmaceutical Industries

$34.37

-0.1-0.29%

At Close 4:00 PM

56.19

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Teva Pharmaceutical Industries Limited (TEVA) stock declined over -0.29%, trading at $34.37 on NYSE, down from the previous close of $34.47. The stock opened at $34.59, fluctuating between $34.20 and $34.73 in the recent session.

Stock Snapshot

34.47

Prev. Close

39.42B

Market Cap

34.195

Day Low

28.4

P/E Ratio

1.21

EPS (TTM)

0.75

Cash Flow per Share

34.59

Open

1.15B

Number of Shares

34.73

Day High

99.52%

Free Float in %

6.7

Book Value

6.13M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 10, 2026	34.59	34.73	34.20	34.37	5.44M
Feb 09, 2026	34.57	34.63	34.27	34.47	7.53M
Feb 06, 2026	35.00	35.11	34.61	34.69	6.42M
Feb 05, 2026	34.90	35.26	34.20	34.80	10.55M
Feb 04, 2026	36.18	36.59	34.88	34.96	11.07M
Feb 03, 2026	35.53	37.35	35.53	36.25	21.57M
Feb 02, 2026	34.45	35.69	34.15	35.52	18.63M
Jan 30, 2026	32.49	34.11	32.35	34.08	16.88M
Jan 29, 2026	33.26	33.44	32.19	33.07	10.52M
Jan 28, 2026	31.39	33.38	30.94	33.21	21.76M
Jan 27, 2026	32.22	32.56	31.57	32.53	14.13M
Jan 26, 2026	31.90	32.20	31.62	32.14	12.11M
Jan 23, 2026	31.62	32.03	31.50	31.81	5.33M
Jan 22, 2026	31.54	31.85	31.42	31.66	6.45M
Jan 21, 2026	31.45	31.79	31.22	31.41	6.51M
Jan 20, 2026	30.78	31.94	30.70	31.36	7.21M
Jan 16, 2026	32.33	32.37	31.58	31.76	7.17M
Jan 15, 2026	32.25	32.76	32.00	32.35	8.84M
Jan 14, 2026	31.95	32.85	31.92	32.64	9.88M
Jan 13, 2026	32.66	32.82	31.98	32.47	7.2M

Contact Details

Tel Aviv, 6944020

Israel

https://www.tevapharm.com 972 391 48213

About Company

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Stock Peers

ZTS

0.83+0.65%

Zoetis Inc.$128.13 CTLT

Catalent, Inc.$63.48 TARO

0.005+0.01%

Taro Pharmaceutical Industries Ltd.$42.98 ELAN

0.78+3.14%

Elanco Animal Health Incorporated$25.61 TAK

0.37+2.09%

Takeda Pharmaceutical Company Limited$18.10 PRGO

0.07+0.49%

Perrigo Company plc$14.39 RDY

-0.14-0.99%

Dr. Reddy's Laboratories Limited$14.04 HLN

0.16+1.47%

Haleon plc$11.04 EBS

0.01+0.09%

Emergent BioSolutions Inc.$11.04 BHC

0.18+3.01%

Bausch Health Companies Inc.$6.16

Company Overview

Teva Pharmaceutical Industries Limited (NYSE:TEVA) closed at $34.37 USD, losing -$0.10 (-0.29%) from the previous close of $34.47. The stock is currently mid-range between its 52-week high and low $12.47 and $37.35. With a market capitalization of about $39.42 billion, Teva Pharmaceutical Industries Limited is classified as a large-cap and shows lower-than-market volatility (beta ~0.72). Key stats such as the average daily volume over the past year has been around 10.58 million shares, volume is running light vs its 52-week average. Headquartered in Tel Aviv, None, Teva Pharmaceutical Industries Limited operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Richard D. Francis, the company employs approximately 37,000 people and listed since February 16, 1982. Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 3.28%, SMA50 9.28%, SMA200 57.92%). The stock’s 14-day RSI is 62.14 (firm momentum), while the ATR of 1.0 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -7.97% below its high and over 175.73% above its low. Average 10-day trading volume of 11.60 million shares is slightly above the 3-month average of 10.43 million, indicating heightened recent market interest.

Valuation Metrics

Teva Pharmaceutical Industries Limited trades at a P/E ratio of 28.0, slightly below the S&P 500 average, with a price-to-sales ratio of 2.28 and a price-to-book ratio of 4.99 trading at moderately above to book value. The P/FCF stands at 34.3, also above market averages.

Dividend & Fair Value

Teva Pharmaceutical Industries Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $5.57. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of 5.52% annually over the next five years. The latest quarter delivered EPS of $0.37. The next quarter is forecast at $0.55. Next year's EPS is expected at $4.38. Analyst sentiment is bullish. Analyst rating data shows there are 8 Strong Buy ratings, 9 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $45.00 to $20.00. The high target offers 30.93% upside. The low target suggests -41.81% downside. The mean target is $33.35. This offers -2.97% upside. Teva Pharmaceutical Industries Limited earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by -45.29%. The prior quarter beat by 4.76%. Over the last six quarters, Apple has recorded several small beats. These include -228.95% in July 31, 2024.

Shareholding & Insider Activity

Teva Pharmaceutical Industries Limited has 1.15 billion shares outstanding. The public float is 1.14 billion shares, elevated short interest at 4.05% of float. This equals 46.26 million shares. The short ratio is 3.73 days. Institutional investors hold 59.01% of the float. Insiders own 0.0%. Kalif Eliyahu Sharon holds 403.29 thousand shares, MIGNONE ROBERTO has 367.60 thousand shares and Francis Richard D has 271.78 thousand shares. Over the past six months, insider transactions show net selling. They sold 623.86 thousand shares across 9 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Teva Pharmaceutical Industries generated $16.54B in revenue, or $14.39 per share. Gross margin was 48.74%, operating margin -1.83%, and net profit margin -9.91%. Returns are negative, with ROA at -3.77% and ROE at -21.84%.
On valuation metrics, Teva Pharmaceutical Industries trades at a P/E of 28.00, P/S of 2.28 and P/B of 4.99. The current ratio is 1.04 and quick ratio is 0.80. Operationally, the company’s inventory turnover is 2.62 and cash conversion cycle is 106.87 days. Debt-to-equity is 2.20, supported by a cash flow-to-debt ratio of 0.09.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2024, Teva Pharmaceutical Industries posted revenue of $16.54B, down slightly from $15.85B in the prior quarter. Gross profit was $8.06B (margin 48.74%). Operating income was - $303.00M (margin -1.8%). Net income was- $1.64B (EPS - $1.45).
The company ended the quarter with $3.23B in cash and short-term investments, a total debt of $20.15B, and net debt of $16.93B. Total assets were $43.48B, with equity of $8.13B. Financials further reflected stability, with operating cash flow of $1.37B, free cash flow of $842.00M, and capital expenditures of - $526.00M.

Price Forecast & Outlook

Our AI price prediction model suggests that Teva Pharmaceutical Industries Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 9.86%, with price expected at $37.76 by February 24, 2026, within a range of $36.95 to $38.49 3-Month Outlook: Projected rise of 85.25%, reaching $63.67 by May 08, 2026, with a range of $62.96 to $64.52. 1-Year Outlook: Projected gain of 19.49%, with price at $41.07 by February 10, 2027, within a range of $39.97 to $42.29.

Key Takeaways

Teva Pharmaceutical Industries Limited (NYSE:TEVA) shares are flat 0.48% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Teva Pharmaceutical Industries Limited trading at a premium to the broader market with a P/E of 28.0. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $21.39, suggesting -37.77% downside. Our AI forecast model points to short-term strength (9.86% over two weeks), a medium-term rise (85.25% over three months), and a longer-term gain (19.49% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Teva Pharmaceutical Industries Limited (TEVA) stock price?

Teva Pharmaceutical Industries Limited (NYSE: TEVA) stock price is $34.37 in the last trading session. During the trading session, TEVA stock reached the peak price of $34.73 while $34.20 was the lowest point it dropped to. The percentage change in TEVA stock occurred in the recent session was -0.29% while the dollar amount for the price change in TEVA stock was - $0.10.

TEVA's industry and sector of operation?

The NYSE listed TEVA is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Teva Pharmaceutical Industries Limited designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of TEVA?

No Data

How TEVA did perform over past 52-week?

TEVA's closing price is 175.62% higher than its 52-week low of $12.47 where as its distance from 52-week high of $37.35 is -7.98%.

How many employees does TEVA have?

Number of TEVA employees currently stands at 37,000.

Link for TEVA official website?

Official Website of TEVA is: https://www.tevapharm.com

How do I contact TEVA?

TEVA could be contacted at phone 972 391 48213 and can also be accessed through its website. TEVA operates from 124 Dvora Hanevi'a Street, Tel Aviv, 6944020, Israel.

How many shares of TEVA are traded daily?

TEVA stock volume for the day was 6.13M shares. The average number of TEVA shares traded daily for last 3 months was 10.58M.

What is the market cap of TEVA currently?

The market value of TEVA currently stands at $39.42B with its latest stock price at $34.37 and 1.15B of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	37000
Beta	0.72
Sales or Revenue	$16.54B
5Y Sales Change%	-0.233%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

TEVA Company Profile and Key Details

Teva Pharmaceutical Industries

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Price Forecast & Outlook

Key Takeaways

Valuation Metrics